Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Marc Dubourdeau (Toulouse, France), Marc Dubourdeau, Gerald Chene, Vincent Baillif, Charlotte Guigne, Estelle Wanecq, Emeline Van Goethem. Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis. Eur Respir J 2016; 48: Suppl. 60, 4041

Member's Comments

No comment yet.

Related content which might interest you: Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 Severe lung inflammation is a feature of IPF Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats? Source: International Congress 2016 – ILD pathogenesis Year: 2016 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015